Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Bms 214778
2. Bms-214778
3. Bms214778
4. N-((2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)propanamide
1. 609799-22-6
2. Hetlioz
3. Vec-162
4. Bms-214778
5. Vec 162
6. Bms 214778
7. Shs4pu80d9
8. Chebi:79042
9. Bms214778
10. Bms-214,778
11. N-(((1r,2r)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)propionamide
12. N-[[(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide
13. N-{[(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide
14. N-(((1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide
15. Propanamide, N-(((1r,2r)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)-
16. Tasimelteon [usan]
17. Tasimelteon [usan:inn]
18. Unii-shs4pu80d9
19. Tasimelteonum
20. N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide
21. Hetlioz (tn)
22. Hetlioz Lq
23. Tasimelteon [mi]
24. Tasimelteon [inn]
25. Tasimelteon (usan/inn)
26. Tasimelteon [vandf]
27. Tasimelteon [mart.]
28. Tasimelteon [who-dd]
29. Gtpl7393
30. Schembl3505912
31. Chembl2103822
32. Tasimelteon, >=98% (hplc)
33. Amy6925
34. Dtxsid70209826
35. Tasimelteon [orange Book]
36. Hms3885l17
37. Act06729
38. Bcp07180
39. Ex-a2729
40. Zinc4392649
41. Mfcd09033789
42. S4281
43. Akos025149360
44. Ac-6143
45. Ccg-266915
46. Cs-5512
47. Db09071
48. Ncgc00522560-01
49. As-35291
50. Hy-14803
51. T3813
52. J3.640.465e
53. D09388
54. 799t226
55. Q7687250
56. N-((2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)propanamide
57. (trans)-n-[[2-(2,3-dihydrobenzofuran-4-yl) Cyclopropyl]methyl]propanamide
58. (trans)-n-[[2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl]methyl]propanamide
59. (-)-(trans)-n-[[2-(2,3-dihydrobenzofuran-4-yl)cycloprop-1-yl] Methyl]propanamide
Molecular Weight | 245.32 g/mol |
---|---|
Molecular Formula | C15H19NO2 |
XLogP3 | 2.2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 4 |
Exact Mass | 245.141578849 g/mol |
Monoisotopic Mass | 245.141578849 g/mol |
Topological Polar Surface Area | 38.3 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 318 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Hetlioz |
PubMed Health | Tasimelteon (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | HETLIOZ (tasimelteon) is a melatonin receptor agonist, chemically designated as (1R, 2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide, containing two chiral centers. The molecular formula is C15H19NO2, and the molecular weight is 24... |
Active Ingredient | Tasimelteon |
Dosage Form | Capsule |
Route | Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Vanda Pharms |
2 of 2 | |
---|---|
Drug Name | Hetlioz |
PubMed Health | Tasimelteon (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | HETLIOZ (tasimelteon) is a melatonin receptor agonist, chemically designated as (1R, 2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide, containing two chiral centers. The molecular formula is C15H19NO2, and the molecular weight is 24... |
Active Ingredient | Tasimelteon |
Dosage Form | Capsule |
Route | Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Vanda Pharms |
Tasimelteon is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).
FDA Label
Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.
N05CH
N - Nervous system
N05 - Psycholeptics
N05C - Hypnotics and sedatives
N05CH - Melatonin receptor agonists
N05CH03 - Tasimelteon
Route of Elimination
Following oral administration of radiolabeled tasimelteon, 80% of total radioactivity was excreted in urine and approximately 4% in feces, resulting in a mean recovery of 84%. Less than 1% of the dose was excreted in urine as the parent compound.
Volume of Distribution
The apparent oral volume of distribution of tasimelteon at steady state in young healthy subjects is approximately 56 - 126 L.
Tasimelteon is extensively metabolized. Metabolism of tasimelteon consists primarily of oxidation at multiple sites and oxidative dealkylation resulting in opening of the dihydrofuran ring followed by further oxidation to give a carboxylic acid. CYP1A2 and CYP3A4 are the major isozymes involved in the metabolism of tasimelteon. Phenolic glucuronidation is the major phase II metabolic route.
The observed mean elimination half-life for tasimelteon is 1.3 0.4 hours.
Tasimelteon is a selective dual agonist of the melatonin receptors MT1 and MT2.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Tasimelteon manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tasimelteon, including repackagers and relabelers. The FDA regulates Tasimelteon manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tasimelteon API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tasimelteon manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tasimelteon supplier is an individual or a company that provides Tasimelteon active pharmaceutical ingredient (API) or Tasimelteon finished formulations upon request. The Tasimelteon suppliers may include Tasimelteon API manufacturers, exporters, distributors and traders.
click here to find a list of Tasimelteon suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tasimelteon DMF (Drug Master File) is a document detailing the whole manufacturing process of Tasimelteon active pharmaceutical ingredient (API) in detail. Different forms of Tasimelteon DMFs exist exist since differing nations have different regulations, such as Tasimelteon USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tasimelteon DMF submitted to regulatory agencies in the US is known as a USDMF. Tasimelteon USDMF includes data on Tasimelteon's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tasimelteon USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tasimelteon suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tasimelteon as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tasimelteon API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tasimelteon as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tasimelteon and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tasimelteon NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tasimelteon suppliers with NDC on PharmaCompass.
Tasimelteon Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tasimelteon GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tasimelteon GMP manufacturer or Tasimelteon GMP API supplier for your needs.
A Tasimelteon CoA (Certificate of Analysis) is a formal document that attests to Tasimelteon's compliance with Tasimelteon specifications and serves as a tool for batch-level quality control.
Tasimelteon CoA mostly includes findings from lab analyses of a specific batch. For each Tasimelteon CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tasimelteon may be tested according to a variety of international standards, such as European Pharmacopoeia (Tasimelteon EP), Tasimelteon JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tasimelteon USP).
LOOKING FOR A SUPPLIER?